Betalactam resistant Streptococcus pneumoniae and management of pneumococcal meningitis;Resistencia de Streptococcus pneumoniae a los betalactámicos y manejo de la meningitis neumocócica

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 1, 2003, Pages 3-6

  Garau, Javier ^a   Martínez Lacasa, Xavier ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CLINAFLOXACIN; DEXAMETHASONE; GARENOXACIN; GATIFLOXACIN; GELATINASE B; GEMIFLOXACIN; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MEROPENEM; NARATRIPTAN; PENICILLIN DERIVATIVE; RIFAMPICIN; TROVAFLOXACIN; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; ZOLMITRIPTAN;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; BRAIN EDEMA; CENTRAL NERVOUS SYSTEM; CONVULSION; EDITORIAL; HAEMOPHILUS INFLUENZAE; HUMAN; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOGENESIS; PUBLICATION; STREPTOCOCCUS PNEUMONIAE;

EID: 0842269675     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042131     Document Type: Editorial

References (32)

1. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. Bacterial meningitis in the United States 1995. N Engl J Med 1997;337:970-8.
2. Soult Rubio JA, Rangel Pineda C, Muñoz Sáez M, Parrilla Parrilla JS, Díaz Fernández F, López Castilla JD, et al. Meningitis neumocócica: características epidemiológicas, clínicas y bacteriológicas. An Esp Pediatr 2001; 55:315-20.
3. Kaul A, Chandwani S. Dexamethasone in bacterial meningitis: To use or not to use? Indian J Pediatr 1996;63:583-9.
4. Tauber MG, Moser B. Cytoquines and chemoquines in meningeal infammation: Biology and clinical implications. Clin Infect Dis 1999;28:1-11.
5. Hoffmann O, Keilwerth N, Bille MB, Reuter U, Angstwurm K, Schumann RR, et al. Triptans reduce the inflammatory response in bacterial meningitis. J Cereb Blood Flow Metab 2002;22:988-96.
6. Leib SL, Leppert D, Clements J, Tauber M. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun 2000;68:615-20.
7. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, et al. Inhibition of matrix proteases and tumour necrosis factor alfa converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 2001;124:1734-42.
8. Meli DN, Christen S, Leib SL, Tauber MG. Current concepts in the pathogenesis of meningitis caused by Streptococcus pneumoniae. Curr Opin Infect Dis 2002;15:253-7.
9. 2 medate brain cell apoptosis during meningitis. J Clin Invest 2002;109:19-27.
10. Bottcher T, Gerber J, Wellmer A, Smirnov AV, Fakhrjanali F, Mix E, et al. Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J Infect Dis 2000;181:2095-8.
11. Cabellos C, Martínez-Lacasa J, Tubau F, Fernández A, Viladrich PF, Linares J, et al. Evaluation of combined ceftriaxone and dexamethasone therapy in experimental cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 2000;45:315-20.
12. Martínez-Lacasa J, Cabellos C, Martos A, Fernández A, Tubau F, Viladrich PF, et al. Experimental study on the efficacy of vancomycin, rifampin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 2002;49:507-13.
13. De Gans J, Van de Beeek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549-56.
14. Paris MM, Hickey SM, Usher MI, Shelton S, Olsen KD, McCracken GH Jr. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994;38:1320-4.
15. Martos A, Cabellos C, Martínez-Lacasa J, Viladrich PF, Gudiol F. Protective effect of dexamethasone and phenytoin in the treatment of experimental pneumococcal meningitis. Enferm Infec Microbiol Clin 1995;13:146-50.
16. Buckingham SC, McCullers JA, Lujan-Zilbermann J, Knapp KM, Orman KL, English BK. Pneumococcal meningitis in children: Relationship of antibiotic resistance to clinical characteristics and outcomes. Pediatr Infect Dis J 2001;20:837-43.
17. Auburtin M, Porcher R, Bruneel F, Scanvic A, Trouillet JL, Bedos JP, et al. Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am J Respir Crit Care Med 2002; 165:713-7.
18. Fernández A, Cabellos C, Tubau F, Liñares J, Viladrich PF, Gudiol F. Relationship between penicillin and cephalosporin resistance of Streptococcus pneumoniae strains and its inflammatory activity in the experimental model of meningitis. Med Microbial Immunol (Berl) 2001;190:135-8.
19. Viladrich PF, Cabellos C, Pallarés R, Tubau F, Martínez-Lacasa J, Linares J, et al. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1996;40:218-20.
20. Oteo J, Cruchaga S, Campos J, Sáez-Nieto JA, Baquero F, y miembros españoles del Grupo del EARSS. Resistencia a antibióticos en Streptococcus pneumoniae aislados de LCR y sangre en 33 hospitales españoles de la Red Europea de Vigilancia de Resistencia a antibióticos (2000). Enf Infec Microbiol Clin 2002;20:12-9.
21. McMaster P, McIntyre P, Gilmour R, Gilbert L, Kakakios A, Mellis S. The emergence of resistant pneumococcal meningitis - implications for empiric therapy. Arch Dis Child 2002;87:207-10.
22. Kaplan SL. Management of pneumococcal meningitis. Pediatr Infect Dis J 2002;21:589-91.
23. Sáez-Llorens X, O'Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J 2001;20:356-61.
24. Odio CM, Puig JR, Feris JM, Khan WN, Rodríguez WJ, McCracken GH Jr, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J 1999;18:581-90.
25. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed meningitis. J Infect Dis 2000;181:369-73.
26. Friedland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCracken GH. Evaluation of antimicrobial regimens for treatment of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993;37:1630-6.
27. Sáez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD, et al. Quinolone treatment for pediatric bacterial meningitis: A comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002;21:14-22.
28. McCracken GH Jr. Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis. Clin Infect Dis 2000;31:45-50.
29. Cottagnoud P, Acosta F, Cottagnoud M, Tauber MG. Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2002;46:1607-9.
30. Cottagnoud P, Acosta F, Cottagnoud M, Pfister M, Tauber MG. Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2002;46:184-7.
31. Cottagnoud P, Gerber CM, Acosta F, Cotagnoud M, Neftel K, Taub MG. Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 2000;46:981-5.
32. Pai VB, Heyneman CA, Erramouspe J. Conjugated heptavalent pneumococcal vaccine. Ann Pharmacother 2002;36:1403-13.